Our Bond stock price rises due to the $250,000 pharmaceutical contract agreement

Investing.com – Our Bond, Inc. (NASDAQ:OBAI) stock rose 4.3% in pre-market trading on Monday after the company announced a business agreement with one of the world’s top five pharmaceutical companies.

The first-phase agreement is valued at approximately $250,000 and covers 5,000 employees out of 100,000 across the pharmaceutical company’s various departments and locations in the United States. This contract establishes a new $250,000 annual recurring revenue stream for Bond, with the potential to expand to over $1 million in the future.

The pharmaceutical company, valued at over $300 billion, will deploy Bond’s AI-driven personal safety platform as part of its 24/7 employee protection program. This agreement marks the beginning of a business relationship between Bond and a global healthcare industry leader.

Bond founder and CEO Doron Kempel said, “Signing business agreements with global leading companies is at the core of our global expansion and revenue growth strategy. We have been focused on enabling the world’s largest companies to adopt Bond services, setting a standard for all enterprises to follow.”

The agreement specifies the deployment of Bond’s AI-driven personal safety platform for designated employee groups and provides a clear path for expansion. Over time, the total contract value could increase to over $1 million, depending on additional scope and future agreements.

Bond’s platform offers real-time preventive safety protection tailored to employees’ roles, locations, and operational conditions. The company’s services are designed for executives, family members, and various employees, including store, branch, laboratory, and clinic staff, sales personnel, drivers, nurses, and social workers.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.